Abstract The “hotness” or “coldness” of the tumors are determined by the information of the
cancer cells themselves, tumor immune characteristics, tumor microenvironment, and …

Immune checkpoint blockade (ICB) induces a remarkable and durable response in a subset
of cancer patients. However, most patients exhibit either primary or acquired resistance to …

The management of patients with brain metastases has become a major issue due to the
increasing frequency and complexity of the diagnostic and therapeutic approaches. In 2014 …

Purpose Broadening trial eligibility to improve accrual and access and to better reflect
intended-to-treat populations has been recognized as a priority. Historically, patients with …

Highlights•A melanoma consensus conference, organised by the ESMO Guidelines
Committee, was attended by 32 experts from 14 countries•The experts compiled …

Immune checkpoint inhibitors, including those targeting the programmed cell death
1/programmed cell death ligand 1 and cytotoxic T lymphocyte antigen 4 pathways, are …

Radiotherapy (RT) is currently used in more than 50% of cancer patients during the course
of their disease in the curative, adjuvant or palliative setting. RT achieves good local control …

Background and purpose While the combination of stereotactic radiosurgery (SRS) and
immune checkpoint inhibitors (ICI) is becoming more widely used in the treatment of brain …

Immune checkpoint inhibitors targeting programmed cell death 1 (PD-1), programmed cell
death ligand-1 (PD-L1), and others have shown potent clinical efficacy and have …

The development of immunotherapy in oncology builds upon many years of scientific
investigation into the cellular mechanics underlying interactions between tumor cells and …